Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)

Inclusion Criteria: * Has histologically confirmed diagnosis of RCC with clear cell component with or without sarcomatoid features * Has locally advanced/metastatic disease (i.e., newly diagnosed Stage IV RCC per American Joint Committee on Cancer) or has recurrent disease * Has measurable disease per RECIST 1.1 as assessed by the investigator/site radiologist * Has received no prior systemic therapy for advanced RCC. * Has provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated. * Has Karnofsky performance status (KPS) ≥ 70% as assessed within 10 days prior to randomization. * If receiving bone resorptive therapy (including but not limited to bisphosphonate or RANK-L inhibitor) must have therapy initiated at least 2 weeks prior to randomization. * Demonstrates adequate organ function. * Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study drug. * Male participants of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study drug through 120 days after the last dose of study drug. Exclusion Criteria: * Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to randomization. * Has had major surgery within 4 weeks, received radiation …